Ch Biotech R&D Co., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia. Founded in 2002, the company has established itself as a pioneer in biopharmaceutical research and development, focusing on innovative solutions for healthcare challenges. Specialising in the development of biologics and biosimilars, Ch Biotech R&D Co. is recognised for its commitment to quality and scientific excellence. Their core products include advanced therapeutic proteins and monoclonal antibodies, which are distinguished by their efficacy and safety profiles. With a strong market position, Ch Biotech R&D Co. has achieved significant milestones, including successful collaborations with global pharmaceutical firms. Their dedication to research and development continues to drive advancements in the biotechnology industry, making them a trusted name in biopharmaceutical innovation.
How does Ch Biotech R And D Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ch Biotech R And D Co's score of 6 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Ch Biotech R And D Co reported total carbon emissions of approximately 3,260,880 kg CO2e, comprising 437,910 kg CO2e from Scope 1, 3,260,880 kg CO2e from Scope 2, and 140,920 kg CO2e from Scope 3 emissions. This marked a reduction from 2021, where total emissions were about 3,388,350 kg CO2e, with Scope 1 emissions at 444,390 kg CO2e, Scope 2 at 3,458,040 kg CO2e, and Scope 3 at 92,920 kg CO2e. Despite these reductions, Ch Biotech R And D Co has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company operates within a global context where many organisations are increasingly focusing on sustainability and carbon neutrality, yet it appears to be in the early stages of formalising its climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2021 | 2022 | |
---|---|---|
Scope 1 | 444,390 | 000,000 |
Scope 2 | 3,458,040 | 0,000,000 |
Scope 3 | 92,920 | 000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ch Biotech R And D Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.